Background
Methods
Study design
Definitions
Procedures
Laboratory measurements
Angiographic analysis
Statistics
Results
Normal UA (n = 251) | Higher UA (n = 66) | p-value | |
---|---|---|---|
Age (year) | 64.6 ± 9.9 | 65.3 ± 10.3 | 0.609 |
Men, n (%) | 182 (72.5) | 57 (86.4) | 0.030 |
Body mass index | 24.8 ± 3.0 | 25.6 ± 2.9 | 0.056 |
Current smoker, n (%) | 61 (24.3) | 16 (24.2) | 1.000 |
Hypertension, n (%) | 175 (69.7) | 53 (80.3) | 0.122 |
Diabetes, n (%) | 91 (36.3) | 25 (37.9) | 0.920 |
Prior MI, n (%) | 69 (27.5) | 23 (34.8) | 0.308 |
Diagnosis at the index PCI | |||
SA/UA, n (%) NSTEMI/STEMI, n (%) | 210 (83.7) 41 (16.3) | 54 (81.8) 12 (18.2) | 0.863 |
Laboratory findings | |||
Uric acid (mg/dL) | 4.9 ± 1.1 | 7.4 ± 1.6 | <.001 |
Total cholesterol (mg/dL) | 150.1 ± 37.3 | 148.8 ± 43.8 | 0.817 |
LDL-C (mg/dL) | 85.9 ± 29.5 | 90.6 ± 36.4 | 0.345 |
HDL-C (mg/dL) | 43.6 ± 11.0 | 42.0 ± 12.7 | 0.333 |
Triglyceride (mg/dL) | 127.5 ± 75.6 | 147.2 ± 78.1 | 0.064 |
Glucose (mg/dL) | 122.5 ± 42.0 | 121.8 ± 42.9 | 0.900 |
Creatinine Clearance (mL/min) | 72.3 ± 22.5 | 63.3 ± 26.2 | 0.006 |
hsCRP (mg/L) | 4.3 ± 10.6 | 5.8 ± 12.9 | 0.407 |
LVEF (%) | 56.2 ± 7.9 | 53.5 ± 11.4 | 0.095 |
Medications | |||
DAPT | 248 (98.8) | 64 (97.0) | 0.610 |
Anti-hyperuricemic agent | – | 18 (27.3) | – |
Normal UA (n = 257) | Higher UA (n = 71) | p-value | |
---|---|---|---|
Previous PCI characteristics | |||
Stent type | |||
BMS, n (%) | 21 (8.3) | 5 (7.5) | |
1st generation DES, n (%) | 88 (34.9) | 35 (52.2) | 0.075 |
2nd generation DES, n (%) | 108 (42.9) | 21 (31.3) | |
3rd generation DES, n (%) | 35 (13.9) | 6 (9.0) | |
Stent diameter (mm) | 2.9 ± 0.3 | 2.9 ± 0.3 | 0.900 |
Stent length (mm) | 22.7 ± 7.2 | 22.0 ± 7.5 | 0.504 |
Median duration between previous PCI to the index procedure (day) | 990 | 1669 | 0.045 |
Lesion characteristics at the index PCI | |||
Target vessel, n (%) | |||
LAD | 166 (64.6) | 49 (69.0) | 0.478 |
LCX | 40 (15.6) | 7 (9.9) | |
RCA | 51 (19.8) | 15 (21.1) | |
Multivessel involvement, n (%) | 166 (64.6) | 53 (74.6) | 0.147 |
CTO, n (%) | 17 (6.6) | 7 (9.9) | 0.502 |
ISR type (II, III, IV), n (%) | 95 (37.0) | 38 (53.5) | 0.017 |
Procedures of the index PCI | |||
PCI type | |||
DES | 174 (67.7) | 52 (73.2) | 0.455 |
DCB | 83 (32.3) | 19 (26.8) | |
DES type | |||
1st generation DES, n (%) | 17 (9.8) | 7 (13.5) | 0.354 |
2nd generation DES, n (%) | 116 (66.7) | 29 (55.8) | |
3rd generation DES, n (%) | 41 (23.6) | 16 (30.8) | |
DES diameter (mm) | 2.9 ± 0.4 | 3.0 ± 0.5 | 0.010 |
DES length (mm) | 23.1 ± 11.5 | 23.8 ± 10.3 | 0.685 |
DCB diameter (mm) | 2.8 ± 0.3 | 2.9 ± 0.3 | 0.344 |
DCB length (mm) | 20.2 ± 5.2 | 20.0 ± 5.1 | 0.875 |
Normal UA | Higher UA | p-value | |
---|---|---|---|
Index PCI | |||
n
| 257 | 71 | |
Pre-procedural RVD (mm) | 2.9 ± 0.4 | 3.0 ± 0.5 | 0.055 |
Pre-procedural MLD (mm) | 0.6 ± 0.4 | 0.6 ± 0.4 | 0.396 |
Pre-procedural DS (mm) | 79.0 ± 12.6 | 78.5 ± 12.4 | 0.749 |
Pre-procedural lesion length (mm) | 20.1 ± 11.0 | 20.2 ± 10.2 | 0.959 |
Post-procedural MLD (mm) | 2.7 ± 0.4 | 2.8 ± 0.6 | 0.105 |
Post-procedural DS (%) | 8.6 ± 6.8 | 8.5 ± 11.9 | 0.925 |
Acute gain (mm) | 2.1 ± 0.5 | 2.2 ± 0.6 | 0.293 |
Follow-up CAG | |||
n
| 118 | 32 | |
Median follow-up period (day) | 462 | 527 | 0.559 |
Target lesion RVD (mm) | 2.9 ± 0.5 | 2.9 ± 0.5 | 0.888 |
Target lesion MLD (mm) | 1.9 ± 1.1 | 2.0 ± 1.1 | 0.590 |
Target lesion DS (%) | 36.2 ± 34.2 | 33.4 ± 33.0 | 0.686 |
Late lumen loss (mm) | 0.8 ± 1.1 | 0.8 ± 0.9 | 0.895 |
Binary restenosis, n (%) | 41 (34.7) | 9 (28.1) | 0.622 |
HR | 95% CI | p-value | |
---|---|---|---|
Univariate | |||
Age | 1.000 | 0.981 – 1.019 | 0.992 |
Men | 1.015 | 0.654 – 1.577 | 0.947 |
Body mass index | 0.971 | 0.909 – 1.039 | 0.401 |
Current smoking | 1.587 | 1.067 – 2.359 | 0.022 |
Hypertension | 1.435 | 0.917 – 2.246 | 0.114 |
Diabetes mellitus | 0.929 | 0.629 – 1.372 | 0.712 |
NSTEMI/STEMI at index PCI | 1.170 | 0.727 – 1.884 | 0.518 |
LDL-C | 1.009 | 1.002 – 1.015 | 0.008 |
Triglyceride | 1.001 | 0.999 – 1.004 | 0.312 |
Uric acid | 1.110 | 0.980 – 1.257 | 0.100 |
Creatinine clearance | 0.997 | 0.989 – 1.006 | 0.494 |
LVEF | 0.976 | 0.955 – 0.998 | 0.031 |
Previous 1st generation DES | 1.204 | 0.824 – 1.758 | 0.338 |
Multivessel involvement | 1.225 | 0.819 – 1.833 | 0.324 |
CTO lesion | 0.784 | 0.364 – 1.689 | 0.534 |
ISR type (II, III, IV) | 0.951 | 0.647 – 1.400 | 0.800 |
DCB (vs DES) | 1.487 | 0.974 – 2.271 | 0.066 |
Multivariate | |||
Current smoking | 1.521 | 0.957 - 2.416 | 0.076 |
Hypertension | 1.469 | 0.870 - 2.481 | 0.150 |
LDL-C | 1.011 | 1.003 - 1.019 | 0.006 |
LVEF | 0.972 | 0.948 - 0.996 | 0.022 |
DCB (vs DES) | 1.475 | 0.912 - 2.386 | 0.113 |